Anti-CD33 Antibody PET-CT Imaging for AML Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches for acute myeloid leukemia (AML) are inadequate, particularly for elderly patients, as they are invasive, non-specific, and fail to accurately monitor disease heterogeneity and extramedullary involvement, leading to poor prognosis and treatment outcomes.
Innovation Solution
A non-invasive method using radioactive isotope-labeled anti-CD33 antibodies for PET-CT imaging to detect AML cells, allowing for precise monitoring of disease distribution and treatment response, combined with functional targeted marrow irradiation (fTMI) and chemotherapy for personalized therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If bone marrow biopsy is performed for AML diagnosis, then diagnostic accuracy is improved, but patient comfort and ease of operation deteriorate due to invasive procedure
Solution Approach 1:
The patent replaces the mechanical invasive bone marrow biopsy procedure with a non-invasive molecular imaging technique using radiolabeled anti-CD33 antibodies detected by PET-CT scanning. This substitution eliminates the need for physical tissue sampling while maintaining diagnostic accuracy through molecular-specific detection of AML cells in the bone marrow.
2Ease of operation
If conventional PET tracers (F18-FDG, F18-FLT) are used for AML monitoring, then ease of operation is improved, but measurement precision deteriorates due to non-specific detection
Solution Approach 1:
The patent introduces an intermediary element - the anti-CD33 antibody - that specifically binds to CD33 antigens on AML cells. This antibody acts as a mediator between the radiolabel and the target cells, providing specific molecular recognition while maintaining the ease of PET-CT imaging methodology. The antibody-radiolabel complex serves as a targeted tracer that combines operational convenience with high detection precision.
3Ease of operation
If single-point bone marrow biopsy is performed, then ease of operation is improved, but measurement precision deteriorates due to inability to detect spatial heterogeneity
Solution Approach 1:
The patent transitions from a single-point (zero-dimensional) bone marrow biopsy to a whole-body three-dimensional imaging approach using PET-CT scanning. This dimensional expansion allows simultaneous visualization of AML distribution across multiple bone marrow sites and extramedullary organs, revealing spatial heterogeneity that cannot be detected by localized biopsy while maintaining procedural simplicity through non-invasive imaging.
4Ease of operation
If conventional chemotherapy is administered, then ease of operation is improved, but measurement precision deteriorates due to inability to target high-disease burden sites
Solution Approach 1:
The patent performs preliminary molecular imaging with radiolabeled anti-CD33 antibodies to map the spatial distribution of AML disease burden before administering chemotherapy. This preliminary action identifies high-disease burden sites that require intensified treatment, enabling subsequent precision chemotherapy delivery to targeted regions rather than uniform systemic administration, thereby improving treatment precision while maintaining operational feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides high sensitivity and specificity for AML detection, reveals spatial heterogeneity, and enhances treatment efficacy by targeting high-disease burden sites with precision, thereby improving patient outcomes and reducing toxicity.
Implementation Method 1
a radioactive isotope-labeled anti-CD33 antibody... exposing the subject to PET-CT scanning, and detecting CD33+ PET-CT signal
Data Source
AI summary
Disclosed is a non-invasive PET-CT imaging method for detecting acute myeloid leukemia (AML) or extramedullary disease (EMD) in a subject using a radioactive isotope-labeled anti-CD33 antibody. Also disclosed is a PET-CT imaged-guided method for treating AML or EMD.